# Genenta Science S.p.A.: financial statements, quarterly

GNTA · Nasdaq · CIK 1838716 · [Healthcare](/sectors/healthcare.md)

Pages: [Overview](/companies/gnta.md) · [Financials](/companies/gnta/financials.md) · [Filings](/companies/gnta/filings.md) · [Insiders](/companies/gnta/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/gnta/financials.md?period=annual).

## Balance sheet

| Line item | Unit | period not labelled (2018-12-31) | period not labelled (2019-12-31) | period not labelled (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | [0.0](/filings/0001493152-22-011671.md) | [25.7](/filings/0001493152-22-011671.md) | [0.0](/filings/0001641172-25-001207.md) | [0.0](/filings/0001493152-26-014387.md) | [0.0](/filings/0001493152-26-014387.md) | not reported |
| Current assets | $m | not reported | not reported | [16.5](/filings/0001493152-22-011671.md) | [38.8](/filings/0001493152-24-011999.md) | [31.7](/filings/0001641172-25-001207.md) | [21.3](/filings/0001493152-26-014387.md) | [14.5](/filings/0001493152-26-014387.md) | [30.0](/filings/0001493152-26-014387.md) |
| Total assets | $m | not reported | not reported | [17.5](/filings/0001493152-22-011671.md) | [40.0](/filings/0001493152-24-011999.md) | [33.4](/filings/0001641172-25-001207.md) | [22.3](/filings/0001493152-26-014387.md) | [14.8](/filings/0001493152-26-014387.md) | [31.9](/filings/0001493152-26-014387.md) |
| Current liabilities | $m | not reported | not reported | [2.3](/filings/0001493152-22-011671.md) | [1.1](/filings/0001493152-24-011999.md) | [2.2](/filings/0001641172-25-001207.md) | [1.7](/filings/0001493152-26-014387.md) | [2.1](/filings/0001493152-26-014387.md) | [2.1](/filings/0001493152-26-014387.md) |
| Shareholders' equity | $m | [7.9](/filings/0001493152-22-011671.md) | [18.9](/filings/0001493152-23-013272.md) | [15.2](/filings/0001493152-24-011999.md) | [38.9](/filings/0001641172-25-001207.md) | [31.1](/filings/0001493152-26-014387.md) | [20.4](/filings/0001493152-26-014387.md) | [12.5](/filings/0001493152-26-014387.md) | [21.8](/filings/0001493152-26-014387.md) |

- Cash and equivalents: us-gaap:Cash, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

Shares outstanding: 23,432,183 at 2025-12-31, from the cover of the [20-F filed 2026-04-01](/filings/0001493152-26-014387.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.